Avelumab is a Monoclonal Antibody owned by Merck, and is involved in 132 clinical trials, of which 44 were completed, 85 are ongoing, and 3 are planned.

Avelumab (MSB-0010718C) is a human monoclonal antibody directed against the CD274 protein ligand PD-L1 (Programmed Death-1 Ligand 1). The drug candidate has immunomodulating and potential anti-neoplastic activities. PD-1 (Programmed Death 1) enhances the T-cell-mediated immune response to neoplasms and reverses T-cell inactivation in chronic infectious disease. It attaches to a protein on the surface of tumor cells. This protein may prevent the immune system (especially white blood cells) from destroying the tumor cells. Anti-PD-L1 monoclonal antibody binds to PD-L1, blocking its binding to and activation of its receptor.

The revenue for Avelumab is expected to reach a total of $15.3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Avelumab NPV Report.

Avelumab is originated and owned by Merck.

Avelumab Overview

Avelumab (MSB-0010718C, Bavencio) is a programmed human IgG1 lambda monoclonal antibody. It is formulated as solution and concentrate solution for intravenous route of administration. Avelumab is indicated for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma. It is also indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) who have disease progression during or following platinum-containing chemotherapy, or who have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy, in combination with axitinib is indicated  for the first-line  treatment of patients with advanced renal cell carcinoma (RCC), and for maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy.

Avelumab (MSB-0010718C) is under development for the treatment of advanced or metastatic squamous anal cancer (SCCAC), adenocarcinoma of the gastro esophageal junction, gastric cancer, homologous-recombination deficient (HRD) ovarian cancer, diffuse large b-cell lymphoma, non-small cell lung cancer, bladder cancer, metastatic transitional cell carcinoma of the urothelium including the bladder, urethra, renal pelvis, and ureter, epithelial ovarian cancer, fallopian tube cancer, peritoneal cancer, head and neck cancer squamous cell carcinoma, epithelial ovarian cancer, fallopian tube cancer, peritoneal cancer, TNBC, squamous non-small cell lung cancer, colorectal cancer, neuroendocrine carcinoma, renal pelvis cancer, upper urinary tract cancer and bladder cancer, urethral cancer, progressing tenosynovial giant cell tumor/pigmented villonodular synovitis,  follicular lymphoma, hepatocellular carcinoma, metastatic hormone refractory (castration resistant, androgen-independent) prostate cancer, muscle invasive bladder cancer (MIBC), recurrent head and neck cancer squamous cell carcinoma, endometrial cancer, peripheral t-cell lymphomas (PTCL),anaplastic large cell lymphoma (ALCL),natural killer cell lymphomas, transformed mycosis fungoides, angioimmunoblastic t-cell lymphoma (AITL)/immunoblastic lymphadenopathy, angiosarcoma, glioblastoma (GBM),small-cell lung cancer, osteosarcoma, relapsed acute myeloid leukemia, refractory acute myeloid leukemia, malignant mesothelioma, hepatobiliary system tumor, adrenocortical carcinoma (adrenal cortex cancer), head and neck cancer squamous cell carcinoma, pancreatic cancer, mantle cell lymphoma, meningioma, squamous cell carcinoma, penile cancer and precancerous condition. It was also under development for the treatment of neuroendocrine gastroenteropancreatic tumors (GEP-NET), neuroendocrine tumors, renal cell carcinoma, Hodgkin lymphoma (B-Cell Hodgkin lymphoma), gastric cancer, melanoma, adenocarcinoma of the gastroesophageal junction (third-line therapy), epithelial ovarian cancer (first line therapy, second-line therapy),fallopian tube cancer, peritoneal cancer, non-small cell lung cancer (second line therapy), cervical cancer, Merkel cell carcinomax, nasopharyngeal cancer, leiomyosarcoma, pancreatic ductal adenocarcinoma, relapsed /refractory multiple myeloma, colon cancer, central nervous system tumor, glioma and head and neck cancer.

Merck Overview

Merck, a subsidiary of E. Merck KG, is a science and technology company. It discovers, develops and manufactures prescription drugs to treat cancer, multiple sclerosis and infertility; and develops liquid crystal mixtures, organic light-emitting diode (OLED) materials, cosmetic active ingredients, pigments for coatings, and high-tech materials. Merck also provides a wide range of products including lab water systems, gene editing tools, cell lines, antibodies and end-to-end systems. The company serves healthcare, performance materials, and life sciences markets. It has presence in Europe, North America, Asia-Pacific, Latin America and Middle East and Africa. Merck is headquartered in Darmstadt, Hesse, Germany.

The company reported revenues of (Euro) EUR19,687 million for the fiscal year ended December 2021 (FY2021), an increase of 12.3% over FY2020. In FY2021, the company’s operating margin was 21.2%, compared to an operating margin of 17% in FY2020. In FY2021, the company recorded a net margin of 15.5%, compared to a net margin of 11.3% in FY2020. The company reported revenues of EUR5,806 million for the third quarter ended September 2022, an increase of 4.3% over the previous quarter.

Quick View – Avelumab

Report Segments
  • Innovator (NME)
Drug Name
  • Avelumab
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Musculoskeletal Disorders
  • Non Malignant Disorders
  • Oncology
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.